Get the Stockscreener App
1,022.02
0.66%
-6.81
After Hours:
1020.00
-2.02
-0.20%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,022.02, with a volume of 2.65M.
It is down -0.66% in the last 24 hours and down -3.83% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,028.83
Open:
$1024.08
24h Volume:
2.65M
Relative Volume:
0.81
Market Cap:
$964.13B
Revenue:
$65.18B
Net Income/Loss:
$20.64B
P/E Ratio:
45.24
EPS:
22.5894
Net Cash Flow:
$5.96B
1W Performance:
-0.12%
1M Performance:
-3.83%
6M Performance:
+38.86%
1Y Performance:
+11.69%
1-Day Range:
$1,007.38
$1,026.91
1-Week Range:
$1,002.46
$1,064.45
52-Week Range:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,022.02 | 970.55B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.47 | 590.83B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
224.69 | 401.23B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
203.98 | 319.13B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
165.51 | 318.38B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly Shares Weather Competitive Pricing Move - AD HOC NEWS
The Next Magnificent 7? 4 Large Caps Gaining Momentum - Investing.com
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy HQ - Inside INdiana Business
Eli Lilly begins using ‘mind-blowing’ LillyPod supercomputer at Indy campus - Indianapolis Business Journal
Eli Lilly Prevails in Appeal of Licensor’s Drug Royalty Claim - Bloomberg Law News
9th Circ. Undoes $278M Eli Lilly Payment In Insulin Case - Law360
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics - The Chronicle-Journal
Eli Lilly Strengthens Market Leadership as Rival Stumbles - AD HOC NEWS
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. - aol.com
Assessing Eli Lilly: Insights From 13 Financial Analysts - Benzinga
Eli Lilly acquires Orna Therapeutics for $2.4B to disrupt CAR-T market - thestreet.com
Eli Lilly (LLY) Releases Positive Results From Phase 3 VIVID-2 Open-Label Extension Study - Finviz
Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact - Finviz
Bernstein reiterates Eli Lilly stock rating after Novo pricing move By Investing.com - Investing.com Canada
Ozempic Price War - Benzinga
Eli Lilly stock price forecast: Steadies around $1,042 after recent pullback - Traders Union
Novo Nordisk's Loss Is Eli Lilly's Gain - Yahoo Finance Singapore
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $1,250 to $1,300 - 富途牛牛
Novo Nordisk To Slash GLP-1 Drug Prices By Up To 50% In US Starting 2027 - Benzinga
Eli Lilly Strengthens Lead in Weight-Loss Drug Market with New Clinical Data - AD HOC NEWS
Eli Lilly Strengthens Market Lead with Clinical and Commercial Wins - AD HOC NEWS
Eli Lilly stock price dips after-hours as Zepbound pen news meets Novo’s Wegovy price-cut plan - Bez Kabli
Eli Lilly Drops After Novo Nordisk Unleashes Massive GLP-1 Price Cuts - GuruFocus
RBC Capital initiates Eli Lilly stock with outperform rating - Investing.com
Novo Slashes GLP-1 Prices Again, Touts New Weight Loss Data on Heels of Lilly Loss - BioSpace
Eli Lilly vs. Novo Nordisk: A Tale of Two Stocks - InvestorPlace
A Tale of Two Titans: Eli Lilly Surges as Novo Nordisk Stumbles in the Weight Loss Price War - The Chronicle-Journal
Novo Nordisk and Eli Lilly shares both fall after Novo’s price-cut plan for Ozempic and Wegovy - MSN
Novo Nordisk to slash Ozempic and Wegovy list prices by up to 50% for 2027 - AOL.com
BofA reiterates Eli Lilly stock rating on limited GLP-1 impact - Investing.com
Eli Lilly (LLY) Unaffected by Novo Nordisk's GLP-1 Price Cuts - GuruFocus
Novo Nordisk vs Eli Lilly: Why the ‘king of weight loss’ just lost its crown - The Financial Express
CSL taps Lilly to de-risk IL-6 drug following dismal earnings - BioWorld MedTech
Eli Lilly (LLY) Shares Fall as Novo Nordisk Slashes Drug Prices - GuruFocus
Eli Lilly Strengthens Position in Weight-Loss Drug Market with New Formulation and Clinical Data - AD HOC NEWS
Novo And United’s Triple G Agonist Outpaces Lilly Rival On Weight Loss - Citeline News & Insights
Eli Lilly (LLY) Shares Dip as Novo Nordisk Announces Price Cuts - GuruFocus
Eli Lilly (LLY) Faces Price Competition as Rival Cuts Drug Costs - GuruFocus
Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead. - Reuters
Eli Lilly: Conservative 2026 Guide, Diversified Pipeline, and Capital Flexibility Underscore Buy Rating Amid Obesity Leadership - TipRanks
Goldman Sachs Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,260 - 富途牛牛
Eli Lilly Strengthens Lead in Weight-Loss Drug Market - AD HOC NEWS
How Novo Nordisk Lost Its Lead in the Weight-Loss Market - Bloomberg
Novo-Nordisk A/S's CagriSema has suffered a head-to-head defeat, losing to Eli Lilly and Co's tirzepatide. - 富途牛牛
Eli Lilly's Strategic Momentum: Pipeline Progress and Patient-Centric Innovation - AD HOC NEWS
Is Eli Lilly Stock Underperforming the S&P 500? - Barchart.com
Analysis-Novo's stumbles burnish Lilly's widening lead in weight-loss drugs - Yahoo! Finance Canada
Zacks Market Edge Highlights: MasTec, Caterpillar, Walmart, Eli Lilly and Howmet Aerospace - The Globe and Mail
Eli Lilly Strengthens Its Lead in the Weight-Loss Drug Arena - AD HOC NEWS
Weight-Loss Drug Rivalry: Novo-Nordisk A/S Suffers Major Defeat Against Eli Lilly and Co, Stock Price Plummets! - 富途牛牛
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):